CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Nov. 17, 2026 /PRNewswire/ --Â Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other areas, today announced that its partner Spruce Biosciences (Nasdaq: SPRB) ("Spruce") has separated its CRHX-101 (formerly SPR-202 and HBM9013) program into Adrenyx Biosciences ("Adrenyx").

kAmp5C6?JI :D 2 ?6H=J 6DE23=:D965[ H9@==J\@H?65 DF3D:5:2CJ @7 $ACF46 7@4FD65 @? 6?5@4C:?@=@8J] %9:D 4@>A2?J :D 6IA64E65 E@ 36 =:DE65 @? }2D52B :? E96 7:CDE 92=7 @7 a_af] &A@? 4@>A=6E:@? @7 E96 A=2??65 AC@ C2E2 5:DEC:3FE:@? @7 p5C6?JI 4@>>@? DE@4< E@ $ACF46 D92C69@=56CD[ w2C3@FC q:@|65 6IA64ED E@ 9@=5 6BF:EJ :?E6C6DED :? 3@E9 $ACF46 2?5 p5C6?JI]k^Am
kAmr#w)\`_` :D 2 >@?@4=@?2= 2?E:3@5J 56D:8?65 E@ D6=64E:G6=J ?6FEC2=:K6 4@CE:4@EC@A:?\C6=62D:?8 9@C>@?6 Wr#wX[ 2? FADEC62> 5C:G6C @7 25C6?2= 2?5C@86? 6I46DD :? 4=2DD:4 4@?86?:E2= 25C6?2= 9JA6CA=2D:2 WrpwX] qJ E2C86E:?8 r#w 2E E96 E@A @7 E96 9@C>@?2= D:8?2=:?8 42D4256[ r#w)\`_` :D 36:?8 56G6=@A65 H:E9 E96 A@E6?E:2= E@ 249:6G6 5FC23=6 FADEC62> 5:D62D6 4@?EC@= 2?5 C65F46 A2E:6?EDV C6=:2?46 @? 49C@?:4 9:89\5@D6 8=F4@4@CE:4@:5 E96C2AJ[ 2 =@?8DE2?5:?8 492==6?86 :? rpw >2?286>6?E] p5C6?JIVD ?62C\E6C> AC:@C:E:6D :?4=F56 4@>A=6E:@? @7 x}s\6?23=:?8 ?@?4=:?:42= 2?5 496>:DECJ[ >2?F724EFC:?8 2?5 4@?EC@=D 24E:G:E:6D[ E96 7:=:?8 @7 2? x?G6DE:82E:@?2= }6H sCF8 2AA=:42E:@? 7@C r#w)\`_` H:E9 E96 &]$] u@@5 2?5 sCF8 p5>:?:DEC2E:@? WE96 QuspQX[ 2?5 :?:E:2E:@? @7 2 4=:?:42= AC@8C2> E96C627E6C]k^Am
kAm%@ DFAA@CE E96 56G6=@A>6?E @7 r#w)\`_`[ p5C6?JI 92D D64FC65 2? :?:E:2= &$Sd >:==:@? F?56C 2 D64FC65 4@?G6CE:3=6 ?@E6 AFC492D6 2CC2?86>6?E[ H:E9 E96 A@E6?E:2= E@ :DDF6 FA E@ &$S`_ >:==:@? :? 288C682E6 AC:?4:A2= 2>@F?E] x? 255:E:@?[ 2 AC:G2E6 A=246>6?E @7 p5C6?JI 6BF:EJ D64FC:E:6D E@ :?DE:EFE:@?2= :?G6DE@CD :D 6IA64E65 E@ 36 4@>A=6E65 :? 4@??64E:@? H:E9 E96 A=2??65 5:DEC:3FE:@?[ H:E9 FA E@ kDA2? :5lQDA2?w89=Eh`d2Qm&$k^DA2?mSd_ >:==:@? 7F?565 3J E96 4@?G6CE:3=6 ?@E6D :?G6DE@C[ :?4=FD:G6 @7 E96 ?@E6D 7F?5:?8]k^Am
kAmsC] y:?8D@?8 (2?8[ u@F?56C[ r92:C>2? 2?5 rt~ @7 w2C3@FC q:@|65[ 4@>>6?E65i Q(6 2C6 A=62D65 E@ D66 E96 4@?E:?F65 25G2?46>6?E @7 r#w)\`_` E9C@F89 2 565:42E65 4@CA@C2E6 DECF4EFC6] %96 6DE23=:D9>6?E @7 p5C6?JI C67=64ED 2 7@4FD65 2AAC@249 E@ 25G2?4:?8 r#w)\`_` 2?5 DFAA@CE:?8 :ED ?6IE DE286 @7 56G6=@A>6?E] (6 =@@< 7@CH2C5 E@ E96 4@?E:?F65 AC@8C6DD @7 r#w)\`_` :? 255C6DD:?8 E96 D:8?:7:42?E F?>6E >65:42= ?665D @7 A6@A=6 =:G:?8 H:E9 rpw]Qk^Am
kAmr#w)\`_` @C:8:?2E65 7C@> wq| p=A92 %96C2A6FE:4D Wwq|p%X[ 2? :??@G2E:G6 3:@E649?@=@8J 4@>A2?J :?4F32E65 3J w2C3@FC q:@|65] x? y2?F2CJ a_ad[ wq|p% 6?E6C65 :?E@ 2 4@==23@C2E:@? 2?5 =:46?D6 28C66>6?E H:E9 $ACF46[ 8C2?E:?8 $ACF46 6I4=FD:G6 C:89ED E@ 56G6=@A 2?5 4@>>6C4:2=:K6 E9:D >@=64F=6 @FED:56 vC62E6C r9:?2 W:?4=F5:?8 >2:?=2?5 r9:?2[ w@?8 z@?8[ |242F 2?5 %2:H2?X] &?56C E96 28C66>6?E[ wq|p% :D 6=:8:3=6 E@ C646:G6 FA E@ kDA2? :5lQDA2?w89=E_gc7Qm&$Sk^DA2?mbhd >:==:@?[ :?4=F5:?8 FA7C@?E[ 56G6=@A>6?E[ C68F=2E@CJ 2?5 4@>>6C4:2= >:=6DE@?6 A2J>6?ED[ 2D H6== 2D E:6C65 C@J2=E:6D @? 7FEFC6 ?6E AC@5F4E D2=6D] p55:E:@?2==J[ wq|p% H2D 8C2?E65 2 H2CC2?E E@ C646:G6 >:?@C:EJ :?E6C6DE :? E96 A2CE?6C] x? y2?F2CJ a_ae[ w2C3@FC q:@|65 2??@F?465 E92E :ED H9@==J\@H?65 DF3D:5:2CJ 925 6I6C4:D65 E96 H2CC2?ED]k^Am
kAmkDEC@?8mp3@FE w2C3@FC q:@|65k^DEC@?8mk^Am
kAmw2C3@FC q:@|65 Wwzt)i _a`caX :D 2 8=@32= 3:@A92C>246FE:42= 4@>A2?J 4@>>:EE65 E@ E96 5:D4@G6CJ 2?5 56G6=@A>6?E @7 ?@G6= 2?E:3@5J E96C2A6FE:4D :? :>>F?@=@8J[ @?4@=@8J 2?5 @E96C 2C62D] %96 r@>A2?J :D 3F:=5:?8 2 C@3FDE A@CE7@=:@ 2?5 5:776C6?E:2E65 A:A6=:?6 E9C@F89 :?E6C?2= #U2>Ajs 42A23:=:EJ[ DEC2E68:4 8=@32= 4@==23@C2E:@?D :? 4@\5:D4@G6CJ 2?5 4@\56G6=@A>6?E[ 2?5 D6=64E:G6 24BF:D:E:@?D]k^Am
kAm~FC AC@AC:6E2CJ 2?E:3@5J E649?@=@8J A=2E7@C>[ w2C3@FC |:46kDFAm®k^DFAm[ 86?6C2E6D 7F==J 9F>2? >@?@4=@?2= 2?E:3@5:6D :? 3@E9 E96 4@?G6?E:@?2= EH@ 962GJ 2?5 EH@ =:89E 492:? Wwa{aX 7@C>2E 2?5 E96 962GJ 492:?\@?=J Wwrp3X 7@C>2E] qF:=5:?8 FA@? wrp3 2?E:3@5:6D[ E96 wrp3\32D65 :>>F?6 46== 6?8286CD WwqxrtkDFAm®k^DFAmX 3:DA64:7:4 2?E:3@5J E649?@=@8J 6?23=6D EF>@C\<:==:?8 67764ED E92E EC25:E:@?2= 4@>3:?2E:@? E96C2A:6D 42??@E 249:6G6] %96 wrp3\32D65 p?E:3@5J !=FD E649?@=@8J Wwrp3 !{&$™X AC@G:56D 4@>AC696?D:G6 >@52=:EJ D@=FE:@?D 7@C E96 56G6=@A>6?E @7 :??@G2E:G6 >F=E:\DA64:7:4 >65:4:?6D :? 5:776C6?E 5:D62D6 2C62D] p55:E:@?2==J[ 3F:=5:?8 FA@? E96 w2C3@FC |:46kDFAm®k^DFAm A=2E7@C>[ w2C3@FC q:@|65 =2F?4965 :ED 7:CDE 7F==J 9F>2? v6?6C2E:G6 px wrp3 |@56= A@H6C65 3J :ED wF\>pECxI™ px A=2E7@C>[ 2446=6C2E:?8 E96 56G6=@A>6?E @7 :??@G2E:G6 E96C2A:6D]k^Am
kAmqJ :?E68C2E:?8 w2C3@FC |:46kDFAm®k^DFAm[ wqxrtkDFAm®k^DFAm[ wrp3 !{&$™[ 2 D:?8=6 q\46== 4=@?:?8 A=2E7@C> 2?5 px E649?@=@8:6D[ w2C3@FC q:@|65 92D 3F:=E 2 9:89=J 677:4:6?E 2?5 5:DE:?4E:G6 2?E:3@5J 5:D4@G6CJ 6?8:?6 7@C 56G6=@A:?8 ?6IE\86?6C2E:@? E96C2A6FE:4 2?E:3@5:6D] u@C >@C6 :?7@C>2E:@?[ A=62D6 G:D:E k2 9C67lQ9EEAi^^HHH]92C3@FC3:@>65]4@>^Q E2C86ElQ03=2?<Q C6=lQ?@7@==@HQmHHH]92C3@FC3:@>65]4@>k^2m]k^Am
kA :5lQ!&#{Qmk:>8 E:E=6lQr:D:@?Q H:5E9lQ`aQ 96:89ElQ`aQ 2=ElQr:D:@?Q DC4lQ9EEADi^^6586]AC?6HDH:C6]4@>^4^:>8^72G:4@?]A?8nD?lr}hg_beU2>AjD5la_ae\``\`fQ ^m ':6H @C:8:?2= 4@?E6?E E@ 5@H?=@25 >F=E:>65:2ik2 :5lQ!#}&#{Q C6=lQ?@7@==@HQ 9C67lQ9EEADi^^HHH]AC?6HDH:C6]4@>^?6HD\C6=62D6D^92C3@FC\3:@>65D\A2CE?6C\DACF46\3:@D4:6?46D\D6A2C2E6D\4C9I\`_`\AC@8C2>\:?E@\25C6?JI\3:@D4:6?46D\25G2?4:?8\56G6=@A>6?E\@7\92C3@FC\3:@>65\@C:8:?2E65\2?E:3@5J\E9C@F89\2\DE2?52=@?6\4@>A2?J\b_ahcahfe]9E>=Q E2C86ElQ03=2?<Qm9EEADi^^HHH]AC?6HDH:C6]4@>^?6HD\C6=62D6D^92C3@FC\3:@>65D\A2CE?6C\DACF46\3:@D4:6?46D\D6A2C2E6D\4C9I\`_`\AC@8C2>\:?E@\25C6?JI\3:@D4:6?46D\25G2?4:?8\56G6=@A>6?E\@7\92C3@FC\3:@>65\@C:8:?2E65\2?E:3@5J\E9C@F89\2\DE2?52=@?6\4@>A2?J\b_ahcahfe]9E>=k^2mk^Am
kAm$~&#rt w2C3@FC q:@|65k^Am
kAmk:>8 2=ElQQ DC4lQ9EEADi^^CE]AC?6HDH:C6]4@>^CE]8:7n}6HDxE6>x5lr}hg_beU2>Aj%C2?D>:DD:@?0x5la_ae```f`h_a!#0}t($0&$!#00000r}hg_beU2>Ajs2E6x5la_ae```fQ DEJ=6lQ3@C56Ci_AIj H:5E9i`AIj 96:89Ei`AIjQ ^mk^Am

